



Published in final edited form as:

Epigenomics. 2026 February ; 18(2): 205–215. doi:10.1080/17501911.2026.2630841.

EpiSmoker2: a robust epigenetic classifier for smoking status inference using Illumina EPIC methylation data

Tianyu Zhu^{a,b,c,*}, Teodóra Faragó^{a,b,*}, Sailalitha Bollepalli^b, Aino Heikkinen^{a,b}, Mikaela Hukkanen^{a,b}, Olli Raitakari^{d,e,f,g}, Terho Lehtimäki^h, Tellervo Korhonen^b, Jaakko Kaprio^b, Fang Fangⁱ, Kaitlyn G. Lawrence^j, Dale P. Sandler^k, Mari Roberts Spildrejorde^{l,m}, Kristina Gervin^l, Yanyu Panⁿ, Ricardo Costeiraⁿ, Jordana T Bellⁿ, Miina Ollikainen^{a,b}

^aMinerva Foundation Institute for Medical Research, Helsinki, Finland

^bInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

CONTACT Tianyu Zhu, tianyu.zhu@helsinki.fi; Miina Ollikainen, miina.ollikainen@helsinki.fi, Minerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, Helsinki 00290, Finland.

*These authors contributed equally.

Author contributions

M Ollikainen, T Zhu and T Faragó conceived the project. T Faragó cleaned the phenotype data of YFS and FTC, trained the model and performed validation in FTC. T Zhu processed YFS DNAm data, developed the R package, performed downstream analysis and drafted the manuscript. M Ollikainen provided critical feedback and helped refine the analysis and manuscript. T Zhu and M Ollikainen jointly supervised this work. S Bollepalli provided the R script for EpiSmoker. A Heikkinen and M Hukkanen preprocessed FTC DNAm data. T Korhonen contributed to the Finnish Twin Cohort (FTC) smoking phenotypes. J Kaprio, principal investigator of the FTC, co-designed phenotype and DNA collection. O Raitakari and T Lehtimäki provided YFS data. D Sandler, principal investigator of the GuLF, and K Lawrence co-designed phenotype and DNA collection. F Fang conducted validation of EpiSmoker2 in GuLF. Y Pan, R Costeira, and JT Bell conducted validation of EpiSmoker2 in TwinsUK. M R Spildrejorde and K Gervin conducted validation of EpiSmoker2 in GeNeUp. All authors discussed the results and commented on and approved the final manuscript.

Disclosure statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical declaration

The data collection of YFS was approved by the Ethics Committee of the Hospital District of Southwest Finland on 20 June 2017 (ETMK: 68/1801/2017). All participants gave their written informed consent, and the studies were conducted in accordance with the Declaration of Helsinki. Data protection will be handled according to current regulations as noted next. The data collection of FTC has been approved by the appropriate national research ethics committees, with the most recent approval granted by the Hospital District of Helsinki and Uusimaa ethics board in 2018 (#1799/2017). Blood samples for DNA analyses were collected from each participant after they had signed a written informed consent. Written informed consent of GuLF was obtained from all participants at a home visit. The study protocol was reviewed by the Institute of Medicine in September 2010 and was approved by the Institutional Review Board of the NIEHS. The study is overseen by a Scientific Advisory Board and a Community Advisory Board. Approval for TwinsUK was obtained from the TwinsUK BioBank, approved by the North West – Liverpool Central Research Ethics Committee (reference 19/NW/0187; Integrated Research Application System ID = 258513). This approval supersedes earlier approvals granted to TwinsUK by the St Thomas' Hospital Research Ethics Committee and later by the London – Westminster Research Ethics Committee (reference EC04/015), which have now been subsumed within the TwinsUK BioBank. Ethical approval for data collection and analysis of GeNeUp was granted from the Norwegian Regional Committee for Medical Research Ethics, ref no 2017/1593/REK sor-ost C. The [ClinicalTrials.gov](https://clinicaltrials.gov) identifier is NCT03862365. Written informed consent was obtained from all participants included in the study.

Availability of software

EpiSmoker2 is freely available as an R package at GitHub (<https://github.com/chloezhu/EpiSmoker2>).

^cInstitute of Biotechnology (BI), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland

^dCentre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland

^eResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland

^fDepartment of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland

^gInFLAMES Research Flagship, University of Turku, Turku, Finland

^hDepartment of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

ⁱGenOmics and Translational Research Center, RTI International, Research Triangle Park, NC, USA

^jDLH, LLC, Bethesda, MD, USA

^kEpidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA

^lDepartment of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

^mCenter for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway

ⁿDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK

Abstract

Aim: Tobacco smoking induces persistent DNA methylation (DNAm) changes in blood that can serve as long-term biomarkers for smoking exposure. We aimed to develop and validate a DNAm classifier of smoking status using Illumina EPIC array data.

Methods: We built Epigenetic Smoking status Estimator2 (EpiSmokEr2), a Least Absolute Shrinkage and Selection Operator (LASSO) regression-based DNAm classifier using 511 CpGs from Illumina Infinium MethylationEPIC array (EPIC) data. The model was trained on 1343 samples from the Young Finns Study cohort and validated across six independent datasets from four cohorts and two array platforms (EPIC and EPICv2).

Results: EpiSmokEr2 achieved an average sensitivity of 0.87 and specificity of 0.86 in distinguishing current from never smokers. Predicted smoking status correlated strongly with established DNAm smoking scores and GrimAge, indicating its ability to capture biologically relevant smoking effects. Simulation analysis showed EpiSmokEr2 was robust for up to 10% missing CpGs.

Conclusion: EpiSmokEr2 provides a reliable DNAm-based estimator of smoking status. It is available as an open-source R package on GitHub, facilitating broad use in epidemiological and clinical research.

PLAIN LANGUAGE SUMMARY

Smoking leaves chemical marks on our DNA, like footprints that reveal a person's smoking history. We developed EpiSmokEr2, a tool that reads these marks to tell whether someone currently smokes, used to smoke, or has never smoked. The tool was built using data from Finnish participants and tested in other populations, where it also worked well. EpiSmokEr2 is free to use, and researchers can use it to uncover smoking exposure when people cannot or do not report it accurately. In the future, this tool could also help doctors check a patient's smoking status.

Keywords

DNA methylation; smoking status; biomarkers; LASSO regression; classifier; illumina EPIC array

1. Introduction

Tobacco smoking is a leading risk factor for cardiovascular disease, respiratory disorders, and multiple cancers [1–3]. While self-reported smoking status is widely used in research and clinical practice, it is susceptible to recall bias (inaccurate memory of smoking history), and social desirability bias (deliberate misreporting of smoking status due to stigma) [4,5]. Although metabolic biomarkers such as blood or urine cotinine provide objective measures of recent tobacco exposure, their utility is limited to short-term detection within 24–72 hours since the last tobacco use due to their short half-life [6].

DNA methylation (DNAm) has emerged as a persistent, long-term biomarker of smoking exposure, capturing both current and past smoking behavior in a dose-dependent manner [7–9]. Notably, hypomethylation at cg05575921 mapped to the gene body of *AHRR* (Aryl hydrocarbon receptor repressor) and other smoking-associated CpG sites can discriminate smokers from nonsmokers with area under the curves (AUCs) >0.9 and reflect the recency of cessation [8,10,11]. However, these scores are typically continuous measures and translating them into categorical smoking status (current/former/never smokers) requires thresholding. Due to variability in population characteristics, technological platforms and data processing methods, there is no such threshold that is universally applicable across datasets.

To address these challenges, we previously developed Epigenetic Smoking status Estimator (EpiSmokEr), a machine learning classifier designed for Illumina 450K methylation array data [7]. With the transition from 450K arrays to the more advanced EPIC and EPICv2 arrays, which cover ~900,000 and ~930,000 CpG sites, respectively, compared to 450K's ~480,000 CpG sites, there is a growing need for updated classification tools. In this study, we introduce EpiSmokEr2, a new DNAm-based classifier designed for EPIC and EPICv2 data. We rigorously evaluated its performance in seven independent datasets across four cohorts comprising individuals from different ancestries (European and African) and provide it as an open-source R package to facilitate smoking classification in epidemiological and clinical research.

2. Methods

2.1. Selection and categorization of training samples

The training set is from the Young Finns Study (YFS) cohort [12,13], which includes EPIC samples from 1445 individuals with available smoking information [14]. A detailed description of the YFS dataset is provided in supplementary material. The smoking status at the time of sampling is obtained from self-reported questionnaires, based on the following question: *What is your current smoking status?*

1. Smokes once a day or more often
2. Smokes once a week or more often, but not daily
3. Smokes less often than once a week
4. Attempts to quit smoking
5. Has quit smoking
6. Has never smoked

Participants were categorized into 3 groups:

Never smokers (answer 6),

Former smokers (answer 5),

Current smokers (answers 1, 2, and 4).

Individuals who reported smoking less than once a week (answer 3, occasional smokers) were excluded from the training sample to reduce ambiguity in smoking status, as their DNAm profile (proxied by cg05575921 mapped to *AHRR* gene body [15]) was much closer to those of never smokers than current smokers (Figure S1). Self-reported passive smokers, as well as never smokers who have reported smoking in previous questionnaires were also removed. The final training set consisted of 1343 samples (current-smoker: 274; former-smoker: 337; never-smoker: 732).

2.2. Training of EpiSmoker2

To reduce dimensionality and exclude uninformative probes, CpGs were first filtered based on variability, retaining 192,549 probes with variance above the 75th percentile (variance > 0.00153) within the training dataset. A multinomial LASSO regression model was then trained using *glmnet* R package [16,17], including sex as an unpenalized covariate. The penalization parameter (λ) was determined via cross-validation by minimizing the multinomial deviance, following the same procedure described for EpiSmoker [7]. The final model selected 511 CpGs in a data-driven manner and estimated the weights based on the optimal λ value.

For classification, the model outputs the log-odds of a sample belonging to each of the 3 smoking statuses. These log-odds were converted to class probabilities using the soft-max function, ensuring that the probabilities sum to one across all classes for one individual. The

final smoking status classification was assigned to the category with the highest posterior probability.

2.3. Validation of EpiSmoker2

We evaluated EpiSmoker2 in seven independent datasets across four cohorts: The Finnish Twin Cohort (FTC) [18–20], The GuLF Study (GuLF) [21], TwinsUK [22,23], and the GeNeup Study [24]. A detailed description of these datasets is provided in the supplementary material. Using self-reported smoking status as the reference, we evaluated classification performance by calculating sensitivity and specificity for each smoking category, as well as overall accuracy. The balanced accuracy of each smoking category was calculated as the mean of sensitivity and specificity. The metrics were calculated using the *confusionMatrix* function from *caret* R package [25]. We assessed performance in both 3-class (current, former, never smokers) and 2-class (current vs. never smokers) frameworks, excluding former smokers in the latter due to their ambiguous classification and potential overlap with other groups.

2.4. DNA methylation GrimAge2 and smoking pack-years calculation

DNAm GrimAge2 [26] is an epigenetic biomarker of aging based on DNA methylation patterns. It was calculated based on 9 DNAm-based surrogates of plasma proteins, an estimator of smoking pack-years (DNAm PACKYRS) and 2 demographic characteristics: chronological age and sex. Age acceleration (AgeAccelGrim2) was determined as the residuals from regressing DNAm GrimAge2 on chronological age. We correlated the EpiSmoker2-predicted smoking status with AgeAccelGrim2 as well as DNAm PACKYRS, following established protocols [26].

2.5. Evaluation of EpiSmoker2 robustness to missing CpGs

To assess the robustness of EpiSmoker2 to missing CpGs in the input data, we systematically introduced missing values by randomly excluding 8% to 50% of CpGs in the FT12&16 dataset, covering a range above the baseline missing rate of 7% observed in the original quality-controlled beta matrix. For each missingness percentage (8%, 9%, 10%, 15%, 20%, 30%, 50%), we performed 50 independent iterations of random CpG exclusion and subsequent classification. Model performance was evaluated by comparing the overall accuracy of both 3-class (current/former/never smoker) and 2-class (current/never smoker) classifications against the baseline performance (7% missing CpGs).

3. Results

3.1. EpiSmoker2 model

An overview of workflow is shown in Figure 1. We trained a 3-class LASSO logistic regression model using blood sample DNAm EPIC data from the YFS, with self-reported smoking status. The final model is based on 511 CpGs, a sex and an intercept term (Figure S2). Top CpGs with the highest coefficients were mapped to *AHRR* gene body (cg05575921, cg26703534) and an intergenic smoking-related CpG (cg21566642). These CpGs were enriched in unannotated genomic regions and were underrepresented in TSS200

(two-sided Fisher's exact test, FDR = 4e-6) and first exon regions (two-sided Fisher's exact test, FDR = 8e-3, Figure S3).

3.2. Validation in EPIC datasets

We evaluated our model across seven independent EPIC (v1 and v2) datasets from four cohorts: FTC, GuLF, TwinsUK, and GeNeup (Table 1, Methods). The confusion matrices showing the reference (self-reported) and predicted smoking status can be found in Figure 2(a,b), for FT12&16 FTC sub-cohort, and Figures S4–S9, for other cohorts. To assess the performance of our classifier, we calculated the sensitivity and specificity of classifying individuals into each category, as well as overall accuracy (Table 2, Methods). The 3-class classification only achieved average balanced accuracy (defined as average of sensitivity and specificity) of 0.81, 0.56 and 0.67 for current, former and never smokers respectively across all datasets, primarily due to misclassification of former smokers. When excluding the former smokers, the 2-class classification of current versus never smokers attained a higher average balanced accuracy of 0.86 (Figure 2(d)). Performance varied across populations, with one subset of the GuLF cohort (individuals of African ancestry) showed reduced accuracy compared to those of European ancestry (Table 2, Figure S6). Notably, the model performed well on datasets from the latest platform EPICv2 (Figure 2(d), Table 2).

Among samples with blood cotinine measurements in FT12&16 cohort (112 current, 34 former, and 24 never smokers), EpiSmoker2-predicted smoking statuses were strongly correlated with cotinine levels (Spearman's correlation coefficient $\rho = -0.74$, $p = 2.1 \times 10^{-30}$). The predicted current smokers exhibited significantly higher cotinine levels compared to predicted never smokers, while predicted former smokers displayed intermediate levels, reflecting mixed profiles of current and never smokers (Figure 2(c)).

3.3. EpiSmoker2 predicts biological smoking status

To further explore the high misclassification rate among self-reported former smokers, we examined time since cessation, smoking duration, and pack-years in 60 samples from FT12&16 cohorts and 32 samples from FTC OLD cohort. Although these data were available only for a limited number of individuals, predicted smoking status showed consistent trends: self-reported former smokers with shorter cessation time (Spearman's $\rho = 0.25$, $p = 0.054$), marginally longer smoking duration (Spearman's $\rho = -0.21$, $p = 0.10$), and higher pack-year (Spearman's $\rho = -0.50$, $p = 3.6 \times 10^{-3}$) were often classified as current smokers, whereas those with longer cessation time, shorter smoking duration, and lower pack-years were more often classified as never smokers (Figure S10).

We then correlated EpiSmoker2 classifications with well-established biomarkers of smoking exposure: *AHRR* methylation [15] (smoking-related hypomethylation on cg05575921) and GrimAge2 [26] (an epigenetic clock related to smoking exposure). In the FTC OLD cohort, EpiSmoker2-predicted smoking status consistently correlated with *AHRR* methylation, which was lowest in predicted current smokers, highest in predicted never smokers, and intermediate in former smokers, suggesting that methylation profiles in misclassified cases reflect biological smoking effects (Figure 3(a)). Similar trends were also observed across other independent cohorts (Figures S4–S9). Predicted current smokers also showed

accelerated GrimAge2 aging compared to predicted former or never smokers (Figure 3(b)). Moreover, *AHRR* methylation, GrimAge2 age acceleration, and GrimAge2 pack-years showed stronger correlations with EpiSmokEr2 predictions than with self-reported status (Figure 3(c,d)), supporting its utility in capturing biologically meaningful smoking effects.

3.4. EpiSmoker2 is robust for up to 10% of missing CpGs

A key advantage of EpiSmokEr2 is its incorporation of 511 CpG sites, which ensures robust performance even with partial missing data. To systematically evaluate this, we conducted simulations by artificially introducing varying proportions of missing CpGs (8%, 9%, 10%, 15%, 20%, 30%, 50%) in the FT12&16 test dataset. When compared to the baseline scenario (which contained ~7% missing CpGs), the model maintained high predictive accuracy with up to 10% missing CpGs, demonstrating its robustness to missing data (Figure 4(a,b)).

3.5. Comparison to EpiSmoker

The original EpiSmokEr was developed using Illumina 450K data and ultimately selected 121 CpGs through its model-fitting procedure [7]. Among them, only four CpGs were present in EpiSmokEr2 model, including highly weighted cg05575921 (mapped to *AHRR*) and cg21566642 (an intergenic smoking-related loci). Comparing the model performance of the two models on 450K and EPIC data respectively, we found that EpiSmokEr was better in 450K samples while EpiSmokEr2 remains optimal for EPIC samples (Figure S11). Together, the two tools provide complementary, platform-specific estimators aligned with the ongoing transition from 450K to EPIC in epigenetic epidemiology. The features of EpiSmokEr and EpiSmokEr2 are summarized in Table 3.

3.6. Performance comparison between male and female participants

To assess potential sex-specific differences in model performance, we applied EpiSmokEr2 separately to male and female participants in three FTC datasets (Table S1). In the FT12&16 datasets, where male and female sample sizes are relatively balanced, classification performance was highly comparable between sexes. In contrast, in the FTC EPICv1 and EPICv2 datasets, where there are more female participants, performance appeared higher in females than in males.

3.7. Classification of self-reported never smokers with inconsistent smoking histories

We also examined a subset of uncertain self-reported never smokers with inconsistent smoking histories – individuals who had previously reported smoking or who had documented passive exposure and were excluded from the primary analyses. EpiSmokEr2 classified 2 of 17 individuals in YFS and 18 of 32 individuals in FT12&16 as former smokers, and 1 FT12&16 individual as a current smoker (Figure S12).

4. Discussion

4.1. Performance and advantages of EpiSmoker2

We present EpiSmoker2, an advanced DNAm-based classifier for smoking status that is compatible with EPIC and EPICv2 array data. Our model was rigorously validated in six independent European ancestry datasets across four cohorts, demonstrating robust performance in distinguishing current, former, and never smokers.

Performance in the FTC OLD cohort (EPIC and EPICv2) was slightly reduced compared with FT12&16 cohorts, likely due to differences in smoking status definition. In the FTC OLD cohort, missing smoking-status ($N = 240$) at the time of blood sampling was inferred from the questionnaire completed closest to the sampling date (within 10 years), introducing potential smoking status errors that may have impacted classification accuracy.

Performance was highly comparable between females and males in the FT12&16 dataset, where sample sizes were balanced. Although higher accuracy was observed in females than in males in the FTC OLD cohort (EPIC and EPICv2), this difference is more likely due to the substantially larger number of female participants and uneven distribution of smoking status across sexes, rather than a true sex-specific effect on model performance. Sex was explicitly included as a covariate to account for known sex-related differences in DNAm. While sex contributes to the model, the effect size is small relative to the major smoking-associated CpGs (Figure S2), indicating that the classification is primarily driven by smoking-related DNAm patterns rather than sex-specific effects.

EpiSmoker2 offers two key advantages over existing methods. First, unlike conventional approaches that rely on DNAm scores which require arbitrary cutoffs to determine smoking status, EpiSmoker2 directly outputs smoking status probabilities without the need for post-hoc thresholding. Supplementary analyses indicate broadly comparable performance between score-based classification using optimized thresholds and EpiSmoker2 (Figure S13; Supplementary Methods). However, these approaches are not directly comparable, as DNAm scores are primarily intended to model smoking exposure as a continuous variable in association analyses, whereas EpiSmoker2 is designed for robust categorical inference. We further note that although EpiSmoker2 also outputs smoking probability that is well correlated with cotinine level (Figure S14), these probabilities are best interpreted as complementary measures reflecting classification uncertainty rather than precise estimates of smoking exposure. Second, like the first version, EpiSmoker2 leverages a machine learning framework incorporating a large number of CpG sites compared to previous score-based methods. This not only enhances predictive power but also ensures robustness in the presence of missing CpGs – a common issue in real-world datasets due to probe filtering or platform differences.

4.2. CpG features and biological relevance

Among the CpGs selected in EpiSmoker2, the top-ranked sites overlapped with well-established smoking-associated loci identified in multiple epigenome-wide association studies (EWAS). For instance, cg05575921 and cg26703534 in the *AHRR* gene body and cg21566642 in an intergenic region have been repeatedly highlighted as robust smoking

biomarkers [15,27–29]. While most of the remaining CpGs selected by the model were located in unannotated regions and showed no clear pathway enrichment, their selection suggests that they may capture biologically relevant signals not yet characterized. This highlights a key advantage of machine learning approaches in uncovering predictive features that appear random but may represent novel markers of interest.

4.3. Classification challenges in former smokers

A limitation of our model is the seemingly reduced accuracy in classifying self-reported former smokers. This limitation is likely due to varying definitions of smoking cessation (e.g., time since quitting, smoking intensity prior to cessation), social desirability to report cessation in a health-related survey despite continuing to smoke, possibility for passive smoking or active nicotine replacement therapy (NRT), and the dynamic nature of post-cessation DNAm changes. Thus, former smokers do not represent a biologically homogeneous group, creating substantial overlap between current and former smokers as well as between former and never smokers. Consistent with this interpretation, classification among former smokers was associated with time since cessation, smoking duration, and pack-years, indicating that discrepancies primarily reflect underlying exposure history rather than random model error. Importantly, the biological signal of smoking captured by EpiSmokEr2 may be more relevant for downstream health-risk assessment than strict agreement with self-reported smoking categories. This was further supported by the result that EpiSmokEr2-predicted smoking status showed stronger correlations with both *AHRR* methylation levels and accelerated epigenetic aging than self-reported smoking status. Harmonized and detailed smoking-history variables would further improve interpretability and classification of former smokers.

4.4. Ancestry considerations

While performance was excellent in European ancestry populations, predictive accuracy was reduced in individuals of African ancestry. The discrepancy likely stems from the European ancestry of our training data, as population-specific DNAm patterns have been well-documented for smoking-associated loci [30,31]. Although CpGs with known SNPs were removed from our training set, ancestry-related differences in methylation quantitative trait loci (meQTL) landscapes and baseline DNAm distributions may still influence the magnitude and direction of smoking-associated DNAm changes, thereby affecting model performance. However, many of the CpGs selected by the model map to well-established smoking-associated loci (e.g., *AHRR*) that have been replicated across diverse ancestries in previous epigenome-wide association studies [15,27–29,32]. This suggests that the core biological smoking signal is broadly conserved and that ancestry-specific DNAm effects are likely to be modest on smoking-related DNAm changes. In addition to ancestry-related biological differences, definitions of “current,” “former,” and “never” smoking status may vary across cultural or study-specific contexts [33]. Such variation can lead to label inconsistency between cohorts and likely contributed to the reduced performance. Achieving optimal cross-population performance may therefore require ancestry-specific calibration or harmonized phenotype definitions. Together, these findings emphasize the importance of incorporating more diverse populations into future training datasets.

4.5. Identification of misreporting in questionnaire

To further assess the utility of EpiSmokEr2 in situations where self-reported smoking history may be uncertain, we also evaluated a subset of uncertain self-reported never smokers from the YFS and FTC cohorts. EpiSmokEr2 classified a subset of them as former or current smokers, indicating the presence of detectable smoking-related DNAm signatures. While the true smoking status of these individuals cannot be definitively established due to potential inconsistencies in questionnaire data and the possibility of occasional (non-daily) or sporadic smoking, these results highlight that the classifier reflects underlying biological exposure rather than reliance on categorical self-report. This reinforces the value of DNAm-based classification, particularly in contexts where misreporting or recall bias may affect questionnaire-derived smoking status.

4.6. Future directions

Future predictions could involve further validation in larger, more diverse populations and exploration of longitudinal DNAm changes. Additionally, as single-cell and whole-genome sequencing technologies advance, adapting EpiSmokEr2 to these platforms may further expand its utility in both research and clinical settings.

5. Conclusion

EpiSmokEr2 provides a reliable DNAm-based approach for classifying smoking status across diverse cohorts and array platforms. It improves on traditional score-based methods by giving smoking status directly, using a wide set of CpG sites, and staying reliable even when some probes are missing. While former smokers remain challenging to classify because of heterogeneous cessation patterns, the tool nevertheless captures biologically meaningful smoking effects, as reflected in its strong association with time since cessation, duration of smoking, smoking pack-years, *AHRR* methylation and epigenetic aging. As an open-source and practical resource, EpiSmokEr2 offers an effective solution for enhancing smoking exposure assessment in epidemiological and clinical research.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank all the study participants from YFS, FTC, GuLF, TwinsUK and GeNeup. We also acknowledge the computational resources of the Institute for Molecular Medicine Finland (FIMM) Technology Center.

Figure 1 was partially created with BioRender.com.

The authors used ChatGPT (OpenAI, GPT-5.1) to assist with language polishing of the manuscript. All content was reviewed and verified by the authors.

Funding

This study is supported by the following funds: Academy of Finland [328685, 307339, 297908 and 251316], Sigrid Juselius Foundation, Liv o Hälsa rf, and Finnish Cultural Foundation to MO. Jaakko Kaprio acknowledges support by Academy of Finland Center of Excellence in Complex Disease Genetics [grants 336823 & 352792] and Sigrid Juselius Foundation. The Young Finns Study has been financially supported by the Academy of

Finland: grants 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals [grant X51001]; Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 [grant 755320 for TAXINOMISIS and grant 848146 for To Aition]; European Research Council [grant 742927 for MULTIEPIGEN project]; Tampere University Hospital Supporting Foundation; Finnish Society of Clinical Chemistry; the Cancer Foundation Finland; pBETTER4U_EU (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you; project number: 101080117); CVDLink [EU grant no. 101137278] and the Jane and Aatos Erkko Foundation. TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. The TwinsUK data and analyses were further supported by the European HDHL Joint Programming Initiative funding scheme DIMENSION award [BBSRC BB/S020845/1 and BB/T019980/1 to J.T.B.], and BACMETH award, selected for funding by the ERC consolidator award and funded by the UK Engineering and Physical Sciences Research Council [EP/Y023765/1 to JTB], and by the UK Economic and Social Research Council [ES/N000404/1 to J.T.B.]. The GuLF Long-Term Follow-up Study was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences [ZO1 ES 102945]. The contributions of the NIH author(s) were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. The DNA methylation data analyses were further supported by National Institute on Drug Abuse grant number R01DA048824 (PI: Fang). The GeNeup study was funded by the Research Council of Norway, grant number [275476 and 328657]. All the funders listed above had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data availability statement

YFS: The dataset supporting the conclusions of this article were obtained from the Cardiovascular Risk In Young Finns study which comprises health related participant data. The use of data is restricted under the regulations on professional secrecy (Act on the Openness of Government Activities, 612/1999) and on sensitive personal data (Personal Data Act, 523/1999, implementing the EU data protection directive 95/46/EC). Due to these restrictions, the data can not be stored in public repositories or otherwise made publicly available. Data access may be permitted on a case by case basis upon request only. Data sharing outside the group is done in collaboration with YFS group and requires a data-sharing agreement. Investigators can submit an expression of interest to the chairman of the publication committee (Prof Mika Kähönen, Tampere University, Finland).

FTC: The phenotype and methylation data from the Finnish Twin Cohort used in this study are stored in the Biobank of the Finnish Institute for Health and Welfare (Helsinki, Finland). Qualified researchers may obtain these data through a standardized application procedure (<https://thl.fi/en/statistics-and-data/data-and-services/research-use-and-data-permits>).

GuLF: The GuLF study welcomes collaborative research proposals. For details on access and proposal preparation, please visit: <https://gulfstudy.nih.gov/en/forresearchers.html>. Once approved, de-identified datasets needed to address specific research questions will be shared under an official NIH Data Transfer Agreement. These agreements ensure the confidentiality and privacy of study participants and usually require approval from both NIH and the recipient organization, as well as oversight from an Institutional Review Board.

TwinsUK: The majority of TwinsUK DNA methylation data used in this study are uploaded on the ReShare UK Data Service, under Data collection identifier 853,526. Access to further individual-level data including DNA methylation and phenotype data can be applied for through the TwinsUK cohort data access committee. For information on access and how to apply, see <https://twinsuk.ac.uk/researchers/access-data-and-samples/request-access/>.

GeNeup: The authors confirm that the data supporting the study's findings are included within the article and its supplementary materials. Processed data may be shared upon reasonable request. Individual-level genetic data cannot be provided due to the ethical approvals governing this research.

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century hazards of smoking and benefits of cessation in the United States. *N Engl J Med*. 2013;368(4):341–350. doi: 10.1056/NEJMsa1211128 [PubMed: 23343063]
2. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. *J Am Coll Cardiol*. 2004;43(10):1731–1737. doi: 10.1016/j.jacc.2003.12.047 [PubMed: 15145091]
3. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ*. 2004;328(7455):1519. doi: 10.1136/bmj.38142.554479.AE [PubMed: 15213107]
4. Gorber SC, Schofield-Hurwitz S, Hardt J, et al. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. *Nicotine Tob Res*. 2009;11(1):12–24. doi: 10.1093/ntr/ntn010 [PubMed: 19246437] • Showed that self-reported smoking status is frequently misclassified, motivating objective biomarker-based approaches.
5. Singh PK, Jain P, Singh N, et al. Social desirability and under-reporting of smokeless tobacco use among reproductive age women: evidence from National family Health survey. *SSM - Popul Health*. 2022;19:101257. doi: 10.1016/j.ssmph.2022.101257 [PubMed: 36263294]
6. Murphy SE, Wickham KM, Lindgren BR, et al. Cotinine and trans 3'-hydroxycotinine in dried blood spots as biomarkers of tobacco exposure and nicotine metabolism. *J Expo Sci Environ Epidemiol*. 2013;23(5):513–518. doi: 10.1038/jes.2013.7 [PubMed: 23443235]
7. Bollepalli S, Korhonen T, Kaprio J, et al. EpiSmokEr: a robust classifier to determine smoking status from DNA methylation data. *Epigenomics*. 2019;11(13):1469–1486. doi: 10.2217/epi-2019-0206 [PubMed: 31466478] •• Introduced the original EpiSmokEr classifier, establishing DNA methylation as a robust tool for smoking status classification.
8. Langdon RJ, Yousefi P, Relton CL, et al. Epigenetic modelling of former, current and never smokers. *Clin Epigenet*. 2021;13(1):206. doi: 10.1186/s13148-021-01191-6 •• Demonstrated epigenetic modelling approaches to distinguish current, former, and never smokers using DNA methylation data.
9. Chybowska AD, Bernabeu E, Yousefi P, et al. A blood- and brain-based EWAS of smoking. *Nat Commun*. 2025;16(1):3210. doi: 10.1038/s41467-025-58357-6 [PubMed: 40180905] • Extended smoking-associated epigenetic signatures to both blood and brain, highlighting their systemic nature.
10. BIOS Consortium, Maas SCE, Vidaki A, et al. Validated inference of smoking habits from blood with a finite DNA methylation marker set. *Eur J Epidemiol*. 2019;34(11):1055–1074. doi: 10.1007/s10654-019-00555-w [PubMed: 31494793] •• Validated accurate inference of smoking habits from blood DNA methylation using a limited marker set.
11. Hillary RF, Marioni RE. MethylDetectR: a software for methylation-based health profiling. *Wellcome Open Res*. 2021;5:283. doi: 10.12688/wellcomeopenres.16458.2 [PubMed: 33969230]

12. Åkerblom HK, Uhari M, Pesonen E, et al. Cardiovascular risk in Young Finns. *Ann Med*. 1991;23(1):35–39. doi: 10.3109/07853899109147928 [PubMed: 2036203]
13. Raitakari OT, Juonala M, Ronnema T, et al. Cohort profile: the Cardiovascular risk in Young Finns study. *Int J Epidemiol*. 2008;37 (6):1220–1226. doi: 10.1093/ije/dym225 [PubMed: 18263651]
14. Mishra PP, Mishra BH, Raitoharju E, et al. Gene set based integrated Methylome and transcriptome analysis reveals potential Molecular mechanisms linking cigarette smoking and related diseases. *Omics J Integr Biol*. 2023;27(5):193–204. doi: 10.1089/omi.2023.0028
15. Zeilinger S, Kühnel B, Klopp N, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. Chen A, editor. *PLOS ONE*. 2013;8(5):e63812. doi: 10.1371/journal.pone.0063812 [PubMed: 23691101] • Provided early evidence that tobacco smoking induces widespread and systematic DNA methylation changes.
16. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw*. 2010;33(1). doi: 10.18637/jss.v033.i01
17. Tay JK, Narasimhan B, Hastie T. Elastic net regularization paths for all generalized linear models. *J Stat Softw*. 2023;106(1). doi: 10.18637/jss.v106.i01
18. Kaidesoja M, Aaltonen S, Bogl LH, et al. FinnTwin16: a longitudinal study from age 16 of a population-based Finnish Twin cohort. *Twin Res Hum Genet*. 2019;22(6):530–539. doi: 10.1017/thg.2019.106 [PubMed: 31796134]
19. Kaprio J, Bollepalli S, Buchwald J, et al. The older Finnish Twin cohort — 45 years of follow-up. *Twin Res Hum Genet*. 2019;22 (4):240–254. doi: 10.1017/thg.2019.54 [PubMed: 31462340]
20. Rose RJ, Salvatore JE, Aaltonen S, et al. FinnTwin12 cohort: an updated Review. *Twin Res Hum Genet*. 2019;22(5):302–311. doi: 10.1017/thg.2019.83 [PubMed: 31640839]
21. Kwok RK, Engel LS, Miller AK, et al. The GuLF STUDY: a prospective study of persons involved in the *deepwater Horizon* oil spill response and clean-up. *Environ Health Perspect*. 2017;125(4):570–578. doi: 10.1289/EHP715 [PubMed: 28362265]
22. Moayyeri A, Hammond CJ, Valdes AM, et al. Cohort profile: TwinsUK and Healthy ageing Twin study. *Int J Epidemiol*. 2013;42(1):76–85. doi: 10.1093/ije/dyr207 [PubMed: 22253318]
23. Verdi S, Abbasian G, Bowyer RCE, et al. TwinsUK: the UK adult Twin Registry update. *Twin Res Hum Genet*. 2019;22(6):523–529. doi: 10.1017/thg.2019.65 [PubMed: 31526404]
24. Oslo University Hospital. GeNeUp study: genetics of neurodevelopment in aging population. 2025. Available from: <https://www.ous-research.no/no/anephys/projects/24655>
25. Kuhn M Building predictive models in *R* using the caret package. *J Stat Softw*. 2008;28(5). doi: 10.18637/jss.v028.i05
26. Lu AT, Binder AM, Zhang J, et al. DNA methylation GrimAge version 2. *Aging (Albany NY)* [Internet]. 2022 [cited 2023 Sept 28]; doi: 10.18632/aging.204434
27. Ambatipudi S, Cuenin C, Hernandez-Vargas H, et al. Tobacco smoking-associated genome-wide DNA methylation changes in the EPIC study. *Epigenomics*. 2016;8(5):599–618. doi: 10.2217/epi-2016-0001 [PubMed: 26864933]
28. Joehanes R, Just AC, Marioni RE, et al. Epigenetic signatures of cigarette smoking. *Circ Cardiovasc Genet*. 2016;9(5):436–447. doi: 10.1161/CIRCGENETICS.116.001506 [PubMed: 27651444] • Identified reproducible genome-wide DNA methylation signatures of cigarette smoking in large population cohorts.
29. Dawes K, Andersen A, Reimer R, et al. The relationship of smoking to cg05575921 methylation in blood and saliva DNA samples from several studies. *Sci Rep*. 2021;11(1):21627. doi: 10.1038/s41598-021-01088-7 [PubMed: 34732805] • Characterized the robustness of cg05575921 methylation as a key smoking biomarker across tissues.
30. DeMeo DL, Rybicki BA. DNA methylation and ancestry. The smoke starts to clear. *Am J Respir Crit Care Med*. 2013;188(9):1049–1051. doi: 10.1164/rccm.201309-1644ED [PubMed: 24180440]
31. Elliott HR, Tillin T, McArdle WL, et al. Differences in smoking associated DNA methylation patterns in south asians and europeans. *Clin Epigenet*. 2014;6(1):4. doi: 10.1186/1868-7083-6-4
32. Sun YV, Smith AK, Conneely KN, et al. Epigenomic association analysis identifies smoking-related DNA methylation sites in African Americans. *Hum Genet*. 2013;132(9):1027–1037. doi: 10.1007/s00439-013-1311-6 [PubMed: 23657504]

33. Zellers S, Van Dongen J, Maes HHM, et al. A bivariate Twin study of lifetime cannabis initiation and lifetime regular tobacco smoking across three different countries. *Behav Genet.* 2024;54(5):375–385. doi: 10.1007/s10519-024-10190-1 [PubMed: 39078541]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Article highlights

- Developed EpiSmokEr2, a DNA methylation-based classifier of smoking status compatible with Illumina EPIC and EPICv2 arrays.
- Validated in six independent European population datasets across four cohorts.
- Estimates probabilistic smoking status predictions, eliminating arbitrary cutoffs used in traditional score-based methods.
- Demonstrates robust performance, with high sensitivity/specificity and resilience to missing CpGs.
- Captures biologically relevant smoking effects, strongly correlating with time since cessation, duration of smoking, smoking pack-years, *AHRR* methylation and epigenetic aging measures.
- Available as a freely accessible open-source R package, supporting epidemiological and clinical research.





Figure 1. EpiSmokEr2 study workflow. EpiSmokEr2 was trained on 1343 EPIC samples from the Young Finns Study (YFS) Cohort, with smoking status (current, former, and never) determined by self-reported questionnaires. A 3-class logistic regression model with LASSO penalty (including sex as a fixed covariate) selected 511 discriminative CpGs. For validation, we applied the model to seven independent EPIC and EPICv2 data from four cohorts, assigning smoking status based on the highest predicted probability. Performance was assessed using sensitivity and specificity for each smoking category, as well as overall accuracy. Partially created in BioRender. Zhu, T. (2026) <https://BioRender.com/yku3y2g>.

**Figure 2.**

Validation of EpiSmokEr2. (a) Confusion matrix for EpiSmokEr2 applied to 331 FT12&16 EPIC samples. Numbers represent sample counts with reference (self-reported) smoking status (x-axis) versus predicted status (y-axis). (b) the same as (a), but excluding self-reported former smokers. Predictions were based on probability comparisons between current and never smokers. (c) Boxplot of cotinine levels in predicted current, former and never smokers. The red dashed line (10 ng/ml) indicates the threshold above which individuals are considered to have smoked within 24 hours before blood draw. Spearman's rank correlation coefficients (ρ) and p -values were calculated between cotinine levels and the predicted smoking status, with current smokers (CS), former smokers (FS), and never smokers (NS) coded as 1, 2, and 3, respectively. (d) Barplot showing the balanced accuracy (defined as the mean of sensitivity and specificity) for predicting each class across six independent datasets (excluding the GuLF African ancestry dataset), using self-reported status as reference. CSvsOther, FSvsOther, and NSvsOther correspond to one-vs-rest

evaluations in the 3-class classification. CSvsNS corresponds to 2-class classification of current versus never smokers. The black dashed line shows the mean balanced accuracy per smoking category. Colors indicate datasets.

Abbreviations: CS, current smoker; FS, former smoker; NS, never smoker.




Figure 3.

Correlation between EpiSmokEr2 predictions and DNAm biomarkers. (a) Boxplots showing *AHRR* (cg05575921) methylation levels in the FTC OLD cohort, stratified by reference (self-reported) smoking status (panels) and predicted smoking status (x-axis). Correctly classified samples are shown in red and misclassified samples in blue. (b) Same as (a), but for GrimAge2 age acceleration. (c) Boxplots showing the *AHRR* methylation (left), GrimAge2 age acceleration (middle) and GrimAge pack years (right) in the FT12&16 dataset. Predicted smoking status is shown in red and reference (self-reported) smoking status in blue. Spearman's rank correlation coefficients (ρ) and p -values were calculated

between the smoking-related scores and smoking status, with current smokers (CS), former smokers (FS), and never smokers (NS) coded as 1, 2, and 3, respectively. (d) Same as (c), but for FTC old cohort.

Abbreviations: GrimAge2_Acc, GrimAge2 age acceleration; GApackyrs, GrimAge pack years; CS, current smoker; FS, former smoker; NS, never smoker.




Figure 4.

Robustness of EpiSmoker2 under missing CpGs. (a) Boxplots showing the overall accuracy (y-axis) under varying percentages of missing CpGs (x-axis). For each percentage, CpGs were randomly masked for 50 times, and overall accuracy was derived from 3-class classification. The red dashed line indicates the baseline performance under 7% of missing CpGs. (b) Same as (a), but for 2-class classification of current and never smokers. Abbreviations: CS, current smoker; FS, former smoker; NS, never smoker.

Table 1.

Statistics of the datasets in this study.

Dataset	Total	CS	FS	NS	Sex (F/M)	Age (mean±SD)	Race	Platform
YFS	1343	274	337	732	751/592	41.8 ± 5.1	European	EPIC
FT12&16	331	127	65	139	164/167	25.3 ± 2.2	European	EPIC
FTCOLDv1	701	95	80	526	641/60	65.6 ± 9.4	European	EPIC
GuLF_EA	843	302	181	360	0/843	46.0 ± 11.8	European	EPIC
GuLF_AA	632	214	75	343	0/632	41.4 ± 11.0	African	EPIC
TwinsUK	641	29	235	377	632/9	62.3 ± 9.6	European	EPIC
FTCOLDv2	223	52	69	102	145/78	57.5 ± 7.2	European	EPICv2
GeNeup	1054	185	520	349	498/556	57.5 ± 9.5	European	EPICv2

Abbreviations: SD = standard deviation; CS = current smoker; FS = former smoker; NS = never smoker.

Table 2.
Validation Performance Metrics.

Dataset	Sensitivity	Specificity	Overall accuracy
FT12&16 (<i>N</i> = 331)			0.57
CS vs others	0.57	0.97	
FS vs others	0.60	0.59	
NS vs others	0.57	0.87	
CS vs NS	0.83	0.96	0.90
FTC OLD EPIC (<i>N</i> = 701)			0.57
CS vs others	0.59	0.92	
FS vs others	0.31	0.66	
NS vs others	0.61	0.77	
CS vs NS	0.73	0.91	0.88
GuLF_EA (<i>N</i> = 843)			0.58
CS vs others	0.99	0.64	
FS vs others	0.33	0.79	
NS vs others	0.37	0.96	
CS vs NS	0.99	0.57	0.76
GuLF_AA (<i>N</i> = 632)			0.37
CS vs others	0.96	0.44	
FS vs others	0.20	0.71	
NS vs others	0.04	0.99	
CS vs NS	1.00	0.17	0.49
TwinsUK_EPIC (<i>N</i> = 641)			0.63
CS vs others	0.90	0.97	
FS vs others	0	1	
NS vs others	1	0.18	
CS vs NS	0.90	1	0.99
FTC OLD EPICv2 (<i>N</i> = 223)			0.56
CS vs others	0.65	0.87	
FS vs others	0.58	0.63	
NS vs others	0.49	0.83	
CS vs NS	0.79	0.89	0.86
GeNeup_EPICv2 (<i>N</i> = 1054)			0.57
CS vs others	0.86	0.77	
FS vs others	0.50	0.68	
NS vs others	0.51	0.88	
CS vs NS	0.96	0.82	0.87

Predicted smoking status was compared with self-reported smoking status. For each smoking status category, the sensitivity and specificity values were calculated by comparing that one with the other two categories (3-class classification), and current to never smokers (2-class classification). Overall accuracy is the proportion of all correctly classified samples out of the total number of samples.

Abbreviations: CS = current smoker; FS = former smoker; NS = never smoker.

Table 3.

Comparison of EpiSmokEr and EpiSmokEr2.

Category	EpiSmokEr		EpiSmokEr2	
Array platform used in model training	Illumina 450K	Illumina EPIC	Illumina EPIC	
Training method	3-class LASSO regression	3-class LASSO regression	3-class LASSO regression	
Number of CpGs selected	121 (94 available on EPIC)	121 (94 available on EPIC)	511 (230 available on 450K)	
Intended use	Optimal for 450K datasets	Optimal for EPIC datasets	Optimal for EPIC/EPICv2 datasets	
Limitations	Reduced performance on EPIC due to missing probes	Reduced performance on EPIC due to missing probes	Reduced performance on 450K due to missing probes	